To clarify the incidence of soft tissue sarcoma and gastrointestinal stromal sarcoma in Osaka, Japan, we analyzed Osaka Cancer Registry's data. We identified a total of 6998 cases, except for those of bones and joints, during 1978 -2007. The age-adjusted incidence rate of those sarcomas was 2.7 per 100 000 (male 2.8, female 2.6) person-years. The trend in the incidence for the last 10-year period (1998 -2007) increased significantly overall and for females, while it was not significant for males. Except for cases not otherwise specified, the most prevalent histological subtype was leiomyosarcoma in digestive organs and gastrointestinal stromal sarcoma, followed by leiomyosarcoma excluding that in digestive organs and liposarcoma. Gastrointestinal stromal sarcomas were registered for the first time in 1988 and have increased since 1999, while leiomyosarcomas in digestive organs have decreased. Gastrointestinal stromal sarcoma might have been diagnosed as leiomyosarcoma in digestive organs before using immunohistochemistry.
INTRODUCTION
Soft tissue sarcomas (STSs) are rare mesenchymal neoplasms with heterogeneous differentiation and those may arise in various organs. In the last two decades, diagnosis of subtyping for STSs advanced significantly, because of the accumulating knowledge of molecular mechanisms of the oncogenic mutations as well as the application of immunohistochemical techniques, especially for leiomyosarcomas. Hirota et al. at Osaka University Medical School first found that a large proportion of gastrointestinal stromal tumors (GISTs) were positive for a c-kit gene product, KIT receptor tyrosine kinase (KT) and had gain-of-function mutation of the c-kit gene (1, 2) . In this study, we examined the incidence rates of STSs in Osaka prefecture, and clarified whether the diagnosis with the new techniques reflected their trends by histological group.
SUBJECTS AND METHODS
We employed data from Osaka Cancer Registry (OCR), which started in 1962 and covered all Osaka Prefecture (2010 Census population 8.7 millions, 7% of Japanese population). Details of the registration procedures and the methods were described elsewhere (3) . Data quality and reliability have been fairly satisfactory, and cancer incidence data in Osaka have been accepted for publication in Cancer Incidence in five continents from volume 3 in 1976 to volume 9 in 2007 (4).
We retrieved all incident cases of STS during 1978 -2007, except for those of bones and joints. In OCR, topography and morphology of the neoplasm are corded according to third edition of the International Classification of Diseases for Oncology (ICD-O) (5) . Its histological classification of STS is in accordance with the WHO classification of STS, 2002 (6) ( Table 1) . We calculated the age-standardized incidence rates of STS using the 2000 US 19 age groups standard population (ASR-US) (7) and World standard population (4) .
We used Joinpoint regression analysis, which was developed by the Surveillance, Epidemiology and End Results Program of the US National Cancer Institute, to identify the years, so-called joinpoint, when statistically significant changes in incidence trend occurred. Joinpoint regression analysis software (version 3.5.2) was obtained from the web site of the Statistical Research Applications Branch of the National Cancer Institute, USA (8) The model can estimate the annual percentage change (APC) of each segment between joinpoints and test whether it is significantly different from zero (P , 0.05). The logarithmic age-standardized incidence was used as the dependent variable, and the year of diagnoses was used as the independent variable in the model. We set the number of joinpoints in cancer trends to a minimum of 0 and a maximum of 3 to find the best fit model using a permutation test and assumed constancy and uncorrelated errors in the calculation. The 10-year trends of incidence were evaluated using the estimated average APC with a 95% confidence interval (CI) according to sex by fitting a linear term on the logarithmic scale.
RESULTS
We identified a total of 6998 incident cases (male 3315, female 3683) of STS. The ASR-US of STS was 2.7 (male 2.8, female 2.6) and the ASR-W was 2.0 (male 2.1, female 2.0) per 100 000 person-years during 1978 -2007. The trend in the incidence for the recent 10-year period (1998 -2007) increased significantly, 0.6% (95% CI 0.2, 1.0) per year overall and 1.1 (95% CI 0.6, 1.5) for females by Joinpoint regression analysis, while it was not significant, 0.2 (95% CI 20.4, 0.7), for males ( Fig. 1) .
About one-third (35.2%) of STS were located in the connective, subcutaneous and other soft tissues, followed by digestive organs (21.9%), and retroperitoneum and peritoneum (13.5%) ( Table 2) .
In Table 3 , we showed the total number of incidence, female-to-male ratio and age distributions according to the histological group. Before using KIT staining, most GISTs had been identified as leiomyoma. So we made a category of leiomyosarcomas in digestive organs and gastrointestinal stromal sarcoma (GISS) (malignant GIST). The most common histological subtype was sarcoma NOS (18.0%), which was followed by leiomyosarcoma in digestive organs and GISS (16.5%), leiomyosarcoma excluding that in digestive organs (11.6%), liposarcoma (9.6%) and malignant fibrous histiocytoma (MFH) (9.0%). Kaposi sarcoma might be a possible factor for increasing incidence rates of STS (12, 14) ; however, we found only 11 cases during this whole study period. The female-to-male ratio was 1.1 for total STS, but 0.8 for leiomyosarcoma in digestive organs and GISS. About 7% of the tumors occurred in children (0 -19 years), while majority (54%) occurred in the 20 -64 years age group. The remaining 39% occurred in the elderly aged 65 years. Sarcoma NOS, leiomyosarcoma in digestive organs and GISS, MFH and angiosarcoma occurred mainly in elder people, while rhabdomyosarcoma and PNET occurred mainly in young people and children. Figure 2 shows the trends in the number of incidence for leiomyosarcoma, GISS and endometrial stromal sarcoma (ESS) during the last two decades. GISS was registered for the first time in 1988. The number of incidence for leiomyosarcoma in digestive organs has decreased since 1999, while GISS has increased thereafter. GISS might have been diagnosed as leiomyosarcoma in digestive organs before using immunohistochemistry. The number of incidence for leiomyosarcoma in uterus and ESS was almost constant. (10) reported that the incidence rates were highest among black women (6.26) and the lowest among white women (4.60). This report suggested that the incidence rate differed among races. The trends in the incidence for the last 10-year period (1998 -2007) increased significantly, 0.6% (95% CI: 0.2, 1.0) and 1.1% (0.6, 1.5) per year overall and for females, respectively. Reporting practices and diagnostic changes are both possible explanations for artificial increase. Reporting practices have been almost constant between 1998 and 2007; however, we must consider changes in the opportunities for diagnostic imaging. According to the reports of Health and Welfare Statistics (13) , the number of computed tomography (CT) scans increased rapidly and widely from 107 in 1978 to 511 in 1990 in Osaka. Thereafter, imaging diagnostic techniques such as CT and magnetic resonance imaging (MRI) have been introduced and widely used. Thus, we analyzed the trends in the incidence during 1998 -2007, so the improvement in diagnostics had a little influence on the trends. Some reports from the USA (14) and the European region (12) showed that AIDS-related KS was a major factor for increased incidence of STS. HHV-8 (15), known as KS-associated herpes virus, is the important oncogenic factor with cytokine-induced growth and it might cause the difference in the incidence among areas. We found only 11 cases of Kaposi sarcoma (KS) during this whole study period. The increase observed in OCR cannot be readily explained, but we have to monitor the future trend. Recently, technical methods for diagnosis of STSs progressed remarkably, especially for GISS (16 -18) . In 1998, Hirota et al. (1) reported that most GISTs expressed KIT, a receptor tyrosine kinase encoded by a proto-oncogene c-kit. These findings have led to the development of a highly specific and effective, targeted therapy with imatib methylate, representing a paradigm shift in therapy for malignant disease.
GISS was registered for the first time in 1988 in OCR, and thereafter, only 0 -2 cases per year were registered till 1998. The number of incidence for leiomyosarcoma in digestive organs decreased since 1999, while GISS increased rapidly thereafter. Leiomyosarcoma in digestive organs was almost diminishing, and became only four cases in 2007. This implies that sarcomas in digestive organs have been diagnosed actively using immunohistochemistry, and have had effective therapies widely since 1999 in Osaka. While the number of incidence for leiomyosarcoma in uterus and ESS was almost constant by year (Fig. 2) . Goettsch et al. (19) also reported that the increased incidence of GISTs during 1995 -2003 was related to an increase in the understanding of GIST pathology 
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Incidence of soft tissue sarcoma and the routine availability of the diagnostic immunohistochemical antibody directed to the CD117 antigen. This study was the first description on the overall incidence of STS in Japan, and would help in understanding the trends of STS by histological group. In the last two decades, great efforts have been made to understand the oncogenic mechanism of STS and led to the development of alternative treatment. We should keep monitoring how the diagnostic procedures and the change in the histological classification will affect the future trends of STS.
